Fideuram Intesa Sanpaolo Private Banking S.P.A. Increases Stock Holdings in AbbVie Inc. $ABBV

Fideuram Intesa Sanpaolo Private Banking S.P.A. boosted its stake in AbbVie Inc. (NYSE:ABBV) by 16.4% during the 1st quarter, HoldingsChannel.com reports. The fund owned 185,761 shares of the company’s stock after purchasing an additional 26,142 shares during the quarter. AbbVie makes up 1.4% of Fideuram Intesa Sanpaolo Private Banking S.P.A.’s portfolio, making the stock its 12th biggest holding. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in AbbVie were worth $40,401,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Chelsea Counsel Co. purchased a new stake in AbbVie in the third quarter worth about $26,000. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie in the 4th quarter worth approximately $28,000. Imprint Wealth LLC raised its position in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares in the last quarter. Westend Capital Management LLC purchased a new position in shares of AbbVie in the 4th quarter valued at approximately $29,000. Finally, IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie in the 4th quarter valued at approximately $31,000. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on ABBV. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Morgan Stanley upped their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target for the company in a research report on Thursday, April 30th. William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $253.81.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said its ongoing post-market study for CoolSculpting Elite supports the aesthetics franchise, bolstering the outlook for a business that can diversify revenue beyond core pharma. AbbVie’s CoolSculpting Elite Study Update Strengthens Aesthetics Outlook
• Positive Sentiment: AbbVie’s venetoclax data in chronic lymphocytic leukemia added to confidence in the company’s hematology pipeline and long-term commercialization potential. AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment
• Positive Sentiment: Commentary around AbbVie as a top dividend and value stock continues to highlight its strong cash flow, income appeal, and recent operating momentum. 3 Dividend Stocks to Buy Hand Over Fist in July
• Neutral Sentiment: Several articles framed AbbVie as an attractive long-term portfolio holding versus peers like Johnson & Johnson, but these pieces were largely comparative and not direct new catalysts. J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
• Neutral Sentiment: Analyst estimate revisions were mixed but only slightly trimmed FY2027 earnings expectations, suggesting no major change to the fundamental view.
• Positive Sentiment: Coverage around AbbVie’s Apogee acquisition also pointed to a broader strategic moat and pipeline expansion, which can support sentiment on the stock. AbbVie: Apogee Deal Just Widened An Already Dominant Moat

AbbVie Stock Up 3.9%

NYSE ABBV opened at $260.88 on Friday. AbbVie Inc. has a 52 week low of $184.63 and a 52 week high of $261.64. The firm has a market capitalization of $460.92 billion, a P/E ratio of 128.51, a PEG ratio of 0.82 and a beta of 0.30. The company has a 50-day moving average price of $218.98 and a 200-day moving average price of $220.02.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the prior year, the business posted $2.46 EPS. AbbVie’s revenue was up 12.4% on a year-over-year basis. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is presently 340.89%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.